Vincent A. de Weger

Vincent A. de Weger

Auto-generated profile, based on publicly available information

Vincent A. de Weger

Department of Medical Oncology, Haga Hospital , Den Haag

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
MJMaja de Jonge
Maja de Jonge
VWVincent A. de Weger
Vincent A. de Weger
MDMark A. Dickson
Mark A. Dickson
MLMarlies Langenberg
Marlies Langenberg
ACAxel Le Cesne
Axel Le Cesne
JSJan H.M. Schellens
Jan H.M. Schellens

1 November 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
VWVincent A. de Weger
Vincent A. de Weger
FSFrederik E. Stuurman
Frederik E. Stuurman
JHJeroen J.M.A. Hendrikx
Jeroen J.M.A. Hendrikx
JMJohannes J. Moes
Johannes J. Moes
ESEmilia Sawicki
Emilia Sawicki
SMSerena Marchetti
Serena Marchetti

1 January 2023 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
VWVincent A. de Weger
Vincent A. de Weger
TSTim Schutte
Tim Schutte
IKInge R.H.M. Konings
Inge R.H.M. Konings
COC. Willemien Menke-van der Houven van Oordt
C. Willemien Menke-van der Houven van Oordt
De Weger VA, et al. J Breast Cancer. 2023 Aug;26:e38. https://doi.org/10.4048/jbc.2023.26.e38

3 November 2017 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
VWVincent A. de Weger
Vincent A. de Weger
SGSanjay Goel
Sanjay Goel
RMRoger von Moos
Roger von Moos
JSJan H. M. Schellens
Jan H. M. Schellens
NMNicholas Mach
Nicholas Mach
ULUlrik Lassen
Ulrik Lassen

27 January 2026 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
ABAniek Bonhof
Aniek Bonhof
AHAnouk E Hiensch
Anouk E Hiensch
NWNicolette Wierdsma
Nicolette Wierdsma
LVLinde F Huis In ‘t Veld
Linde F Huis In ‘t Veld
SBSandra D Bakker
Sandra D Bakker
HLHanneke Van Laarhoven
Hanneke Van Laarhoven
Background: Patients with incurable gastroesophageal adenocarcinoma have an impaired health-related quality of life (HRQOL). Exercise combined with nutritional support may improve this outcome. Careful evaluation of this supportive care strategy is needed to avoid burdening patients at this vulnerable stage with interventions that may offer no (meaningful) benefit. Therefore, this study aims to investigate the effects of a combined exercise and nutritional intervention on HRQOL in patients with incurable gastroesophageal adenocarcinoma. Methods: RADICES (the effect of exeRcise And Diet on quality of life in patients with Incurable Cancer of Esophagus and Stomach) is a multicenter randomized controlled trial aiming to include 196 patients with incurable gastroesophageal adenocarcinoma. Participants are randomly assigned (1:1) to a patient-tailored intervention or a control group. The intervention group is provided with 2 training sessions per week and biweekly nutritional consultations, delivered by trained physiotherapists and dietitians, during 12 weeks. The control group receives usual care supplemented with general physical activity advice. The primary outcome is the difference in HRQOL between the intervention group and the control group at 12 weeks, accounting for baseline HRQOL, measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–30 summary score. HRQOL is assessed at baseline, 6 weeks, 12 weeks, and every 3 months thereafter up to 1 year. Key secondary outcomes include patient-reported outcomes, cardiorespiratory fitness, dietary intake, disease progression, overall survival, and cost-effectiveness. Adherence and safety are monitored throughout the intervention period. Conclusion: This study will generate evidence on the effectiveness of a patient-tailored combined exercise and nutritional intervention in patients with incurable gastroesophageal adenocarcinoma. If effective for HRQOL, this intervention could be integrated into standard care for patients with incurable gastroesophageal adenocarcinoma. Trial registration: clinicaltrials.gov NCT06138223. Date of trial registration: November 18, 2023 Date and version study protocol: 28-04-2025 version 3.1 Date start recruitment: 19-01-2024